Drug or treatment

Zanzalintinib clinical trials

• 24Clinical trials
• 31Countries

Newest trials

All recruiting trials (24)

• Zanzalintinib alone or with Pembrolizumab and Berahyaluronidase Alfa in colorectal cancer with molecular residual disease

  This trial tests whether zanzalintinib alone or with pembrolizumab and berahyaluronidase alfa can help people with stage II/III colorectal cancer who still have MRD detected by a Signatera test after surgery.

  Recruiting at 13 sites Phase 3 Exelixis · Council Bluffs, Iowa and 12 other locations · NCT07750158

• Zanzalintinib for Recurrent or Metastatic Olfactory Neuroblastoma

  This study tests whether zanzalintinib can help control recurrent or metastatic olfactory neuroblastoma and whether it is safe.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07527169

• Belzutifan plus zanzalintinib versus belzutifan alone for advanced renal cell carcinoma

  This trial tests whether adding the targeted drug zanzalintinib to belzutifan helps people with advanced renal cell carcinoma live longer and delay tumor growth compared with belzutifan plus placebo.

  Recruiting at 107 sites Phase 3 Merck Sharp & Dohme LLC · Duarte, California and 110 other locations · NCT07489495

• Zanzalintinib for recurrent or progressive meningioma

  This trial tests whether zanzalintinib can help people whose meningioma has come back or kept growing after standard treatments.

  Recruiting at 20 sites Phase 2 Exelixis · Birmingham, Alabama and 19 other locations · NCT07428616

• Zanzalintinib plus pembrolizumab for select advanced soft-tissue sarcomas

  This trial will test whether combining zanzalintinib with pembrolizumab can help control certain advanced or metastatic soft-tissue sarcomas in adults.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07283731

• Belzutifan plus zanzalintinib versus cabozantinib for recurrent advanced kidney cancer after adjuvant PD-1/L1 therapy

  This study will test whether taking belzutifan together with zanzalintinib helps people with recurrent advanced kidney cancer live longer and keep the cancer from getting worse compared with cabozantinib after prior adjuvant PD-1/L1 therapy.

  Recruiting at 127 sites Phase 3 Merck Sharp & Dohme LLC · Anchorage, Alaska and 126 other locations · NCT07227402

• Zanzalintinib for aggressive variant prostate cancer

  This phase 2 study tests whether taking zanzalintinib once daily can help men with aggressive variant prostate cancer.

  Recruiting Phase 2 Hoosier Cancer Research Network · Milwaukee, Wisconsin · NCT07218666

• Zanzalintinib for advanced or metastatic bone sarcomas (ZAMBONE)

  This study will see if zanzalintinib can slow disease progression in adults with advanced or metastatic bone sarcomas.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07193550

• Zanzalintinib with a bone-strengthening agent for metastatic clear cell RCC with bone metastases

  This phase 2 trial tests zanzalintinib plus a bone-strengthening agent in adults with metastatic clear cell renal cell cancer that has spread to bone and progressed after 1–3 prior therapies, including IO therapy.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT07043608

• Zanzalintinib for advanced liver cancer after prior treatment

  This phase Ib/II study tests if zanzalintinib is safe and tolerable and if it can help people with advanced liver cancer after other therapies.

  Recruiting Phase 1/2 Northwestern University · Chicago, Illinois · NCT07042919

• Single-dose zanzalintinib testing in people with moderate liver impairment

  This will test how one dose of zanzalintinib behaves in the blood of people with moderate liver impairment compared with healthy people.

  Recruiting at 2 sites Phase 1 Exelixis · Orlando, Florida and 1 other locations · NCT06962332

• Zanzalintinib before surgery for advanced thyroid cancer

  This will try zanzalintinib before surgery in adults with advanced or locally invasive thyroid cancers to shrink tumors and make surgery safer and less complex.

  Recruiting at 5 sites Phase 2 M.D. Anderson Cancer Center · Boston, Massachusetts and 4 other locations · NCT06959511

• Zanzalintinib plus eribulin for advanced liposarcoma and leiomyosarcoma

  This trial tests whether adding zanzalintinib to eribulin helps adults with advanced liposarcoma or leiomyosarcoma live longer without their cancer getting worse.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT06957431

• Testing XB628 for advanced or metastatic solid tumors

  This study is testing a new treatment called XB628 to see if it can help people with advanced or metastatic solid tumors by finding the right dose that is safe and effective.

  Recruiting at 11 sites Phase 1 Exelixis · San Francisco, California and 10 other locations · NCT06952010

• Zanzalintinib versus everolimus for advanced or metastatic pancreatic and extra‑pancreatic neuroendocrine tumors

  This trial tests whether zanzalintinib works better than everolimus for people with previously treated, unresectable or metastatic pancreatic or extra‑pancreatic neuroendocrine tumors.

  Recruiting at 134 sites Phase 2/3 Exelixis · Birmingham, Alabama and 134 other locations · NCT06943755

• Maintenance zanzalintinib with oral etoposide after high-dose chemotherapy for germ cell tumor

  This treatment tests whether daily zanzalintinib together with cycles of oral etoposide can help people with relapsed or refractory germ cell tumors after high-dose chemotherapy and stem-cell transplant.

  Recruiting Phase 1/2 Indiana University · Indianapolis, Indiana · NCT06937866

• Zanzalintinib maintenance for high-grade neuroendocrine neoplasms

  This trial tests whether taking zanzalintinib after initial chemotherapy can keep high-grade neuroendocrine tumors from growing longer in people with these cancers.

  Recruiting Phase 2 Washington University School of Medicine · Rochester, Minnesota and 1 other locations · NCT06926634

• Zanzalintinib with pembrolizumab and cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial tests whether adding the oral drug zanzalintinib to pembrolizumab and cetuximab is safe and finds the best dose for adults with recurrent or metastatic head and neck squamous cell cancer.

  Recruiting Phase 1 University of Chicago · Chicago, Illinois · NCT06912087

• Combination of XL092 and Immunotherapy for Advanced Clear Cell Kidney Cancer

  This study is testing if a new drug called XL092, alone or with another treatment called nivolumab, can help people with advanced clear cell kidney cancer who haven't responded well to previous therapies.

  Recruiting at 5 sites Phase 2 Hoosier Cancer Research Network · La Jolla, California and 4 other locations · NCT06863311

• Zanzalintinib with paclitaxel for recurrent high-grade uterine cancer

  This trial tests whether adding zanzalintinib to paclitaxel is safe and helps people with recurrent high-grade uterine (endometrial) cancer respond to treatment.

  Recruiting at 2 sites Phase 1 Washington University School of Medicine · San Francisco, California and 3 other locations · NCT06795009

• Zanzalintinib plus nivolumab before surgery for advanced clear cell kidney cancer

  This will try daily oral zanzalintinib together with regular nivolumab infusions for 12 weeks in adults with locally advanced or inoperable clear cell kidney cancer to shrink tumors and see if surgery becomes possible.

  Recruiting at 3 sites Phase 2 Hoosier Cancer Research Network · St Louis, Missouri and 3 other locations · NCT06794229

• Combining Zanzalintinib with Immunotherapy for Liver Cancer

  This study is testing a new combination of a cancer drug and immunotherapy to see if it can help people with advanced liver cancer feel better and fight their disease.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania and 2 other locations · NCT06698250

• Zanzalintinib treatment for advanced leiomyosarcoma

  This study is testing if a new medication called zanzalintinib can help people with advanced leiomyosarcoma live longer without their cancer getting worse.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT06571734

• Zanzalintinib with immune checkpoint drugs for advanced solid tumors

  This trial will test whether zanzalintinib alone or combined with immune drugs (nivolumab, with or without ipilimumab or relatlimab) is safe and helps people with advanced or metastatic solid tumors such as renal cell, prostate, urothelial, and liver cancers.

  Recruiting at 101 sites Phase 1 Exelixis · Phoenix, Arizona and 121 other locations · NCT05176483

Quick answers

How many clinical trials of Zanzalintinib are recruiting right now?

24, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 31 countries. The most sites are in United States (24 trials), Australia (4 trials), France (4 trials), Germany (4 trials), Italy (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 12, Phase 1: 6, Phase 3: 3, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →